Overview
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
Status:
Completed
Completed
Trial end date:
2019-06-10
2019-06-10
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:- Type 2 diabetes treated with a stable dose of metformin at least 500 mg
- HbA1c value between 7.0 and 10.5%
Exclusion Criteria:
- Type 1 diabetes or secondary forms of diabetes